- US11826360utility2023Methods of Treating Fabry Patients Having Renal Impairment0 cites
- US11813255utility2023Methods of Treating Fabry Patients Having Renal Impairment0 cites
- US11786516utility2023Methods of Treating Fabry Patients Having Renal Impairment0 cites
- US11753632utility2023Highly Potent Acid Alpha-glucosidase with Enhanced Carbohydrates0 cites
- US11685718utility2023Highly Purified Batches of Pharmaceutical Grade 1-deoxygalactonojirimycin Compounds0 cites
- US11666564utility2023Methods of Treating Fabry Patients Having Renal Impairment0 cites
- US11642334utility2023Methods of Treating Fabry Patients Having Renal Impairment0 cites
- US11633387utility2023Methods of Treating Fabry Patients Having Renal Impairment0 cites
- US11633388utility2023Methods of Treating Fabry Patients Having Renal Impairment0 cites
- US11622962utility2023Methods of Treating Fabry Patients Having Renal Impairment0 cites
- US11623916utility2023Highly Purified Batches of Pharmaceutical Grade Migalastat and Methods of Producing the Same0 cites
- US11612593utility2023Methods of Treating Fabry Patients Having Renal Impairment0 cites
- US11612594utility2023Methods of Treating Fabry Patients Having Renal Impairment0 cites
- US11602528utility2023Method for the Treatment of Pompe Disease Using 1-deoxynojirimycin Derivatives0 cites
- US11591583utility2023Highly Potent Acid Alpha-glucosidase with Enhanced Carbohydrates0 cites
← PreviousPage 2 of 2